These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16791594)

  • 1. Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy.
    Yonemori K; Ando M; Shibata T; Katsumata N; Matsumoto K; Yamanaka Y; Kouno T; Shimizu C; Fujiwara Y
    J Cancer Res Clin Oncol; 2006 Oct; 132(10):635-42. PubMed ID: 16791594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
    Hainsworth JD; Johnson DH; Greco FA
    J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
    Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
    Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
    van der Gaast A; Verweij J; Planting AS; Hop WC; Stoter G
    J Clin Oncol; 1995 Jul; 13(7):1720-5. PubMed ID: 7541451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination.
    Piga A; Gesuita R; Catalano V; Nortilli R; Cetto G; Cardillo F; Giorgi F; Riva N; Porfiri E; Montironi R; Carle F; Cellerino R
    Oncology; 2005; 69(2):135-44. PubMed ID: 16127284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
    Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
    J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
    Kodaira M; Takahashi S; Yamada S; Ueda K; Mishima Y; Takeuchi K; Yamamoto N; Ishikawa Y; Yokoyama M; Saotome T; Terui Y; Hatake K
    Ann Oncol; 2010 Jun; 21(6):1163-1167. PubMed ID: 20019088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
    Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
    Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.
    Mencel PJ; Motzer RJ; Mazumdar M; Vlamis V; Bajorin DF; Bosl GJ
    J Clin Oncol; 1994 Jan; 12(1):120-6. PubMed ID: 7505805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.
    Briasoulis E; Kalofonos H; Bafaloukos D; Samantas E; Fountzilas G; Xiros N; Skarlos D; Christodoulou C; Kosmidis P; Pavlidis N
    J Clin Oncol; 2000 Sep; 18(17):3101-7. PubMed ID: 10963638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
    Hainsworth JD; Spigel DR; Thompson DS; Murphy PB; Lane CM; Waterhouse DM; Naot Y; Greco FA
    Oncologist; 2009 Dec; 14(12):1189-97. PubMed ID: 19965914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
    Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.
    Smit E; Moro-Sibilot D; Carpeño Jde C; Lesniewski-Kmak K; Aerts J; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Girvan A; Visseren-Grul C; Schnabel PA
    Lung Cancer; 2016 Feb; 92():35-40. PubMed ID: 26775594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
    Ozcan MF; Dizdar O; Dincer N; Balcı S; Guler G; Gok B; Pektas G; Seker MM; Aksoy S; Arslan C; Yalcin S; Balbay MD
    Urol Oncol; 2013 Nov; 31(8):1709-15. PubMed ID: 22863869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.
    Takekuma M; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
    J Gynecol Oncol; 2015 Jul; 26(3):185-92. PubMed ID: 26197856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinoma of unknown primary site.
    Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
    Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.